IPGA17:A potential First-in-class target antagonist for cancer treatment


The TARGET of IPGA17 is a pattern receptor highly expressed on the surface of tumor-associated macrophages (TAM) in the tumor microenvironment (TME). The TARGET plays a role in forming a suppressive immune microenvironment. Tumor-derived exosomes (TDEs) can promote the transformation of macrophages into TAM through the IPGA17 target. Therefore, IPGA17 represents a potential therapeutic strategy against cancer. IPGA17 is a promising first-in-class antagonist antibody that can block the transformation of TAMs induced by TDEs in the TME.

Mechanism of Action

■ Reduction in TAM polarization.

■ Activation of dendritic cells (DCs) and T cells in cancer treatment.